DAX25.261 +0,9%Est506.131 +1,2%MSCI World4.343 -0,1%Top 10 Crypto8,6500 +1,6%Nas22.886 +0,9%Bitcoin57.705 +1,5%Euro1,1758 -0,1%Öl71,73 -0,3%Gold5.099 +2,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Bayer BAY001 SAP 716460 NVIDIA 918422 Siemens Energy ENER6Y Deutsche Telekom 555750 Infineon 623100 Amazon 906866 Lufthansa 823212 Microsoft 870747 RENK RENK73 Airbus 938914 BASF BASF11 DroneShield A2DMAA Siemens 723610
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX und Wall Street gehen stärker ins Wochenende -- Supreme Court stoppt Trump-Zölle -- NVIDIA wohl mit Milliardeninvestment in OpenAI -- Apple, Telekom, BioNTech, Moderna, Diginex, Bayer im Fokus
Top News
Krypto-Kriminalität 2025: CertiK meldet milliardenschweren Schaden durch Hacks und Betrug Krypto-Kriminalität 2025: CertiK meldet milliardenschweren Schaden durch Hacks und Betrug
Hot Stocks heute: Trump vertagt Iran-Krise - Airbus wackelt, thyssenkrupp glänzt Hot Stocks heute: Trump vertagt Iran-Krise - Airbus wackelt, thyssenkrupp glänzt
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Cellectis Aktie

Kaufen
Verkaufen
Cellectis Aktien-Sparplan
3,38 EUR +0,02 EUR +0,60 %
BMN
3,90 USD -0,02 USD -0,51 %
nachbörslich
BTT
Cellectis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone
Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA14QZE

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS15117K1034

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCLLS

Cellectis Aktien News

DatumMeistgelesen
BenzingaAllogene Arbitration Victory Pressures Cellectis Shares Tuesday
BenzingaWhy Cellectis Stock Is Trading Higher Today
BenzingaCellectis Earnings Preview
Wer­bungCellectis-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
GlobeNewswireMonthly information on share capital and company voting rights
GlobeNewswireCellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
GlobeNewswireCellectis Reports Financial Results for the First Quarter 2025
GlobeNewswireMonthly information on share capital and company voting rights
GlobeNewswireCellectis to Report First Quarter Financial Results on May 12, 2025
GlobeNewswireCellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
GlobeNewswireMonthly information on share capital and company voting rights
GlobeNewswireCellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
GlobeNewswireCellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
GlobeNewswireMonthly information on share capital and company voting rights
GlobeNewswireCellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
GlobeNewswireMonthly information on share capital and company voting rights
GlobeNewswireMonthly information on share capital and company voting rights
GlobeNewswireCellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
GlobeNewswireMonthly information on share capital and company voting rights
GlobeNewswireMonthly information on share capital and company voting rights
GlobeNewswireCellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
GlobeNewswireCellectis Provides Business Updates and Financial Results for Third Quarter 2024
GlobeNewswireCellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
GlobeNewswireCellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
GlobeNewswireMonthly information on share capital and company voting rights
GlobeNewswireMonthly information on share capital and company voting rights
GlobeNewswireCellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
GlobeNewswireCellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
GlobeNewswireCellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
GlobeNewswireCellectis Provides Financial Results for the Second Quarter 2024
GlobeNewswireMonthly information on share capital and company voting rights
GlobeNewswireFDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
GlobeNewswireFDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
GlobeNewswireMonthly information on share capital and company voting rights
GlobeNewswireCellectis Reports Results from Shareholders Meeting Held on June 28, 2024
GlobeNewswireCellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
GlobeNewswireCellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
GlobeNewswireMonthly information on share capital and company voting rights
GlobeNewswireCellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
GlobeNewswireCellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
GlobeNewswireCellectis Reports Financial Results for First Quarter 2024

Cellectis News

Cellectis News: auf dieser Seite finden Sie alle Cellectis News und Nachrichten zur Cellectis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Cellectis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Cellectis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.